Tag:

Merck

Latest Headlines

Latest Headlines

UPDATED: Bristol-Myers dominates--and disappoints--at ASCO immuno-oncology debut

Bristol-Myers Squibb and rival Merck started off the big annual scientific meeting of  ASCO  with a bang, rolling out a slate of new studies spotlighting the growing body of evidence that their new immuno-oncology drugs will play a key role fighting a range of cancers.

Merck hands its hep C combo to the FDA with sights on Gilead and AbbVie

Merck, working to scratch out a place in the market for next-generation hepatitis C cures, filed its new combination treatment for FDA approval in hopes of taking third place in a fast-crowding field.

Merck's Keytruda, BMS' Opdivo score European nods to keep immuno-oncology race blazing

Merck's Keytruda gained some regulatory ground in Europe on Friday, nabbing a melanoma recommendation that Opdivo snagged last month. But Opdivo continued to charge ahead, too, winning a nod in lung cancer to help preserve its lead.

PatientsLikeMe nabs Merck informatics veteran to lead R&D

PatientsLikeMe has lured Jason Johnson away from Merck. Johnson is leaving Merck after 14 years at the Big Pharma to head up R&D at PatientsLikeMe, a role which gives him responsibility for efforts to extract insights from patient-reported data.

India's top court orders temporary halt to Glenmark's production of Merck diabetes drugs

India's Supreme Court has called a temporary halt to Glenmark's production of generics of two Merck diabetes drugs but allowed continued sales of the local drugmaker's inventory through October or November.

Merck scores victory in India patent battle over top diabetes meds

Merck scored a victory in its patent battle with India's Glenmark Pharmaceuticals over copycats of the drugmaker's diabetes meds Januvia and Janumet, as India's highest court blocked the generics company from marketing its cheap versions of the drugs in the country.

Moderna tops CNBC's list of most disruptive new technologies

Promising preclinical work on messenger RNA therapies has provided Moderna Therapeutics with the number one spot on CNBC's list of the most disruptive new technologies now in the spotlight.

Lucky 7 diabetes meds to join blockbuster club by 2020

Which diabetes med is likely to be on top in 2020? According to FirstWord Pharma, that would be--surprise!--Lantus, albeit as a $5 billion shadow of its former self. Januvia should keep its hold on second prize with almost $4 billion, while Novo Nordisk's NovoRapid and Lilly's Humalog remain in the top 5 with $3.6 billion and $3.04 billion in sales.

Is there a place for pharma in the emerging EHR market?

More than three-fourths of practices have implemented a basic electronic health record system, according to HHS numbers, and around half now use advanced versions. EHR software vendors have direct access to--and the undivided attention of--those healthcare providers in a whole new way.

Merck or Merck KGaA? German Merck beefs up branding to (hopefully) end confusion

Effective branding is important for any company. But it becomes even more important when you share a name with another company--especially when that other company is your rival.